Case-By-Case Changes To Off-label Promotion
This article was originally published in RPM Report
Executive Summary
While FDA has stuck to a narrow interpretation of precedents like the Caronia ruling, arguing that the decision does not in any way change the landscape for off-label promotion, a series of subsequent court decisions used the Second Circuit’s precedent to solidify company’s free speech protections.